Academic Journals Database
Disseminating quality controlled scientific knowledge


Author(s): Mohammed Jafar | Sadath Ali

Journal: International Research Journal of Pharmacy
ISSN 2230-8407

Volume: 2;
Issue: 5;
Start page: 220;
Date: 2011;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Meloxicam | Solid dispersion | Buccal Patch | In-vitro release | In-vivo release

Arthritis is one of the most common chronic diseases in the world. Life style effects of arthritis includes; Depression, Anxiety, Feelings of helplessness, Limitations on daily activities, Job limitations etc. Meloxicam, a non-steroidal anti-inflammatory drug is widely used in the treatment of rheumatoid arthritis, ankylosing spondulytis and osteoarthritis. It is also indicated for the management of dental pain, Post-traumatic and post-operative pain, inflammation and swelling. Recently it is considered as a potential drug for prevention and treatment of colorectal polyps. One of the major problems with this drug is its low solubility in biological fluids, which results into poor bioavailability and GI-Side effects after oral administration. The present work was aimed at overcoming these limitations of the drug. The first problem i.e. Poor solubility of meloxicam was overcome by solid dispersion technique and the same work was than published in a reputed online journal. The present study was the continuation of the published work, in this study buccal patches were prepared using varying percentage of carbopol 934p, HPMC (muco adhesive polymers) and 50% W/W of propylene glycol (Plasticizer) by solvent casting technique, using 32 factorial design. Prepared blank buccal patches were evaluated for various physical and mechanical parameters, patches which comply with reported results were selected for meloxicam and its solid dispersion incorporation. Meloxicam solid dispersion incorporated buccal patches were prepared and evaluated for drug content, in-vitro diffusion, in-vivo release of meloxicam in rabbits and stability study. All solid dispersion incorporated patches showed increased in-vitro drug release (i.e. between 94% to 99.98%) over an extended period of 8hrs as compared to plain drug incorporated buccal patch. Whereas plain drug incorporated buccal patch showed only 31.22% in-vitro drug release in 8hrs. Release of meloxicam was slightly decreased from the patches when the amount of polymer was increased. Meloxicam solid dispersion incorporated buccal patch (MSM2) containing meloxicam solid dispersion (meloxicam 150mg, PVP250mg, PEG6000 175mg and mixture of lactose and MCC(4:1)4gm) equivalent to 7.5mg of meloxicam, 1.5% of carbopol 934p, 1% of HPMC and 50% of polymer weight of propylene glycol in each 1cm2 of the patch showed highest in-vitro drug release i.e. 99.98% in 8hrs The in-vivo release of meloxicam from its solid dispersion incorporated buccal patches was also studied using rabbit model. A good in-vitro in-vivo correlation was observed in MSM2 patch. All solid dispersion incorporated buccal patches showed excellent stability under tested conditions. Finally it may be concluded that buccal patches were better for improvement of release of meloxicam and also to overcome the gastric side effects of drug.

Tango Jona
Tangokurs Rapperswil-Jona

     Affiliate Program